The latest market price and medical insurance reimbursement policy of Osimertinib

Osimertinib is a third-generation EGFR-TKI, mainly used to treat patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). In the domestic market, osimertinib has been officially launched and has been included in the national medical insurance directory, providing patients with a more convenient way to take the drug. The officially approved specification is 80mg*30 tablets. The latest market price is about five to six thousand yuan. The specific price may vary slightly depending on different regions or hospitals.

In terms of medical insurance reimbursement policy, patients can enjoy a certain percentage of reimbursement for osimertinib that is included in medical insurance and meets the medication indications and medical insurance regulations. Usually, patients who purchase drugs through designated medical insurance pharmacies or hospitals can be reimbursed part of the drug cost according to local medical insurance policies to reduce their financial burden. Medical insurance coverage also encourages patients to purchase through formal channels to ensure reliable sources and controllable quality of drugs.

It is worth noting that in countries such as Laos and Bangladesh, there are also generic osimertinib drugs that are officially on the market. The active ingredients of these generic drugs are basically the same as those of the original drugs, and the quality has been approved by the local drug regulatory department, but the price is significantly lower than the domestic original drugs. 80mg*30 tablets are only sold for a few hundred yuan. This price difference is mainly due to the low R&D costs and different production and distribution models of generic drugs. It also provides an alternative option for some patients with limited financial capabilities.

For patients, drug sources, quality assurance, medical insurance coverage, and financial burden should be comprehensively considered when choosing medications. In China, purchasing the original osimertinib that is covered by medical insurance can not only ensure the efficacy and safety of the drug, but also reduce financial pressure through medical insurance reimbursement. For patients who need to purchase drugs across the border, they should ensure that the source of the drugs is formal and legal and used under the guidance of a doctor to ensure the treatment effect and avoid potential risks.

Reference materials:https://www.drugs.com/

xa0